{
  "name" : "dacemirror.sci-hub.se_journal-article_a46aa0c1775a8b539393c52db8bbdf73_lai2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : null,
    "authors" : [ "Shuping Xu", "Chongyang Liang" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "rsc.li/nanoscale\nNanoscale\nrsc.li/nanoscale\nISSN 2040-3372\nPAPER Shuping Xu, Chongyang Liang et al. Organelle-targeting surface-enhanced Raman scattering (SERS) nanosensors for subcellular pH sensing\nVolume 10 Number 4 28 January 2018 Pages 1549-2172\nNanoscale\nThis is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.\nAccepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.\nYou can find more information about Accepted Manuscripts in the Information for Authors.\nPlease note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.\nAccepted Manuscript\nView Article Online View Journal\nThis article can be cited before page numbers have been issued, to do this please use: C. Lai, W. Tsai, M.\nYang, T. Chou and Y. Chang, Nanoscale, 2019, DOI: 10.1039/C9NR06256D.\nPage 1 of 9 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D"
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\npatients have 3 or more CTCs per 7.5 mL blood, while the median CTC number of all stage IV patients is zero.13, 14 The low CTC capture rate may be attributed to the inherent biological factors such as the low CTC incident rates and cell heterogeneity such as EpCAM negative CTCs in cancer patients, as well as device parameters such as the optimization of antibody-antigen affinity, immunostaining efficiency, or imaging identification. Previous studies showed that some affinity based microfluidic chips outperformed the CellSearch Platform.9, 15 These results indicate that while cell isolation based on immunomagnetic bead is scientifically sound and concept-proven, it is worth of further investigation to improve its efficiency. One of the improvements could come from the re-design of immunomagnetic materials scaffolds.\nIn this study, specifically, we hypothesized that a efficient immunomagnetic scaffold may be designed by considering two conditions: 1) sufficient magnetic force to drag CTCimmunomagnetic scaffold complex from a viscous blood solution, and 2) strong affinity of CTC-immunomagnetic scaffold binding such that no dissociation or severe cell deformation could be taken place during the drag.\nTo satisfy the first condition, we need to maximize the total quantity of magnetic beads attached to a cell surface, as the magnetic force is proportional to the total mass of attached magnetic beads (SI Equation S1).16, 17 While the number of attached beads was inversely proportional to the diameter of the beads, the magnetic force of an individual magnetic bead is linearly proportional to the diameter cubed. Hence, the maximal inserted magnetic force to each target cell would be approximately proportional to the diameter squared. As a result, larger magnetic bead would provide significantly larger magnetic force. For example, using magnetic microbeads of 1\nm in diameter would provide 100 times higher magnetic force than a magnetic nanoparticles (MNPs) of 100 nm in diameter, assuming a full surface coverage in each case.\nHowever, when considering the second condition, the large microbead may not have sufficient adhesion with the target cell relative to its magnetic force as the contact surface between the bead and the target cell is relatively small due to the geometrical hindrance. The bead-cell complex may not withstand the pulling drag during the magnetic separation process, resulting in bead detachments.\nThe binding affinity may be illustrated by the Eq. 1,16, 17, 18 where the binding force (Fc) between a CTC and a magnetic bead is proportional to the effective contact area (Ac).\n-------------------------------------- (Eq. 1), = { + }\nwhere Ac is effective contact area; NR is cell receptor density; kB is Boltzman s constant; O is absolute temperature; lb is the extent of stretch to reach critical force to break single bond (m, 8.8×10-10); NL is substratum ligand density on bead; 4 is fitting specificity; kD is equilibrium dissociation constant.\nEq. 1 elucidates the importance of multivalency (~Ac NR , ~ln(NL)), which plays a pivotal role in biological processes.19 In contrast to weak monovalent recognition, multivalent interactions result in high specificity, and thermodynamic and kinetic stability.19-21 Welldefined nano-materials can be good multivalent carriers in diverse applications.22-28 Magnetic microbeads may provide sufficient\nmagnetic force yet the smaller contact point with the target cell may result in the detachment of microbead-cell complex during the pulling process. On the other hand, smaller beads, such as magnetic nanoparticles (MNPs) (D~10~100 nm) could provide multivalent contact to a CTC, but it has limited magnetic force and the risk of being engulfed by cells, especially white blood cells (WBCs) through endocytosis. 29\nHence, in this study, we propose a magnetic nano-net system to satisfy the two conditions. MNPs coated on a soft and flexible microsize immuno-graphene oxide (GO) sheet can potentially solve the problem by enlarging the overall magnetic force while protecting individual MNPs from endocytosis. As illustrated in Schemes 1a and 1b, the GO material compared to the microbeads provides a large robust two-dimensional (2D) flexible patch area, an excellent platform for multivalent antibody presentation for capturing CTCs. Furthermore, the flexibility of the 2D carbon-based material GO morphs with the cell curvature, therefore further enhancing the multivalency.30 Previous reports have demonstrated that a stable supported lipid bilayer (SLB) can be formed on a GO sheet via vesicle fusion.31, 32 The SLB coating provides a biomimetic, native environment33-35 that can solve the general non-specific binding problems of bare or non-well-surface hydrophilic coating carbon materials.36 Additionally, site-specific biotinylation with four polyethylene glycol (PEG4)-linker on Fc-domain of anti-EpCAM was previously developed to increase the CTC capture ability in colorectal cancer (CRCs) patients samples.37 To this end, we plan to develop an immunomagnetic nano-net with biomimetic lipid non-fouling coating on a micro-size 2D GO sheet surface for rare cell capturing.\nThe immunomagnetic nano-net, Ab@Lipo-MNP-GO, was designed and synthesized by systematic coatings with MNPs, lipids and the site-specific biotinyl anti-EpCAM on GO (Scheme 1c). The intermediate and final products were characterized and confirmed through superconducting quantum interference device (SUQID), Fourier-transform infrared spectrometer (FTIR), thermal gravimetric analysis (TGA), dynamic light scattering (DLS) and scanning electron microscope (SEM), displayed in Figures 1 and 2. The multivalent effect of the antibody arrangement makes the resulting carbon material Ab@Lipo-MNP-GO an excellent platform for selectively wrapping and capturing CTCs from complex mixture (Figures 3 and 4). The immunomagnetic nano-net was then successfully applied to clinic samples and has shown significantly better capture ability than Ab@beads (immunomagnetic microbeads, Figure 5)."
    }, {
      "heading" : "Materials and methods",
      "text" : ""
    }, {
      "heading" : "Materials and Instruments",
      "text" : "All the chemicals and proteins were obtained from commercial\nsources without further purification. This encompasses the\nfollowing: N-(3-dimethylaminopropyl)-N -ethylcarbodiimide\nhydrochloride (EDC, Aldrich), N-hydroxysuccinimide (NHS, Aldrich),\ngraphene oxide (GO, Aldrich, cat. 777676), amino-PEG surface\ncoated magnetic iron oxide nanoparticle (~250 nm, NH2@MNP, nanomag®-D, micromod Partikeltechnologie GmbH, cat. 09-55-252),\nstreptavidin coated magnetic microbeads (SA@beads, size ~1.05 S\nInventogen, Dynabeads MyOne Streptavidin C1), 1-Palmitoyl-2-\noleoyl-sn-glycero-3-phosphocholine (POPC, Avanti Polar Lipids), 1,2-\nPage 2 of 9Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D\nPage 3 of 9 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D\nPage 4 of 9Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D\nPage 5 of 9 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D\nPage 6 of 9Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D"
    }, {
      "heading" : "Journal Name ARTICLE",
      "text" : "This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 7\nPlease do not adjust margins\nPlease do not adjust margins\nAb@Lipo-MNP-GO; by contrast, each Ab@bead only had point\nadhesion on the cell surface. The dramatic difference in\nmorphological arrangement confirms our hypothesis why Ab@Lipo-\nMNP-GO has a much higher capture efficiency than Ab@beads\n(Figures 3 and 4; more cell capture morphologies and additional 3D\nvideos were also provided in SI and Figure S5).\nApplication in clinic patient samples\nFinally, Ab@Lipo-NMP-GO and Ab@beads were examined on eight\npatients including one healthy, two oral cancers, four colorectal\ncancer (CRC) and one non-small cell lung cancer (NCSLC) patients by\nusing 0.5 to 1.0 mL of whole blood. Isolated CTCs were defined with\ntriple immunostaining by Hochest+/panCK+/CD45- for oral cancer\nand NSCLC or Hochest+/CK20+/CD45- for CRC, and WBCs were\ndefined as Hochest+/panCK-/CD45+ in oral and lung cancer patients\nor Hochest+/CK20-/CD45+ in CRC patients. The typical\nimmunostaining images of captured CTCs and WBCs were shown in\nFigure S6, and the result was summarized in Figures 5 and Table S1.\n20 S of Ab@Lipo-NMP-GO had significant higher CTC isolation\nability than Ab@beads. The order of magnitude of CTC quantity\ncaptured by Ab@beads is consistent with those reported previously.11, 15 The CTC counts from our system, however, has\nsignificantly boosted by comparison. In the two cases of oral cancer\npatients (oral-1 and oral-2), while Ab@beads could not retrieve any\nCTCs, Ab@Lipo-NMP-GO was able to capture CTCs in both cases with\ncounts of 65 and 59 per mL of peripheral blood. Furthermore, in the\ncase of oral cancer patient oral-2, even by increasing Ab@beads\namount from 20 S to 100 S no CTC was captured (Table S1). This\nresult suggested clear limitation of using immunomagnetic\nmicrobeads such as CellSearch® system in that the single point\ncontact provides relatively low overall affinity between the target cell\nand beads. This weakness was exemplified on CTCs with low antigen\nexpression level. Meanwhile, the nano-net, Ab@Lipo-NMP-GO,\nsuccessfully captured at least double-digit CTCs per mL of cancer\npatient blood."
    }, {
      "heading" : "Conclusions",
      "text" : "A new magnetic scaffold system was designed for efficiently capturing rare cells from complex fluids. To unlock the clinical utility of CTCs depends on the ability to efficiently detect and isolate sufficient amount of these rare cells using methods amenable to downstream characterization, such as molecular level analysis or other biological applications. We demonstrate that immunomagnetic 2D nano-net, Ab@Lipo-MNP-GO, is a robust multivalent platform to efficiently capture rare cells such as CTCs from whole blood. The synthetic steps were extensively characterized. Confocal images showed that it can wrap around CTCs, and serve as a patch-like multivalent matrix with superparamagnetic property. The 2D network overcomes the drawback of micro-size magnetic beads, with clear advantages when applying to clinical samples. The improved capture ability can bring more information for cancer research. We anticipate that this concept could easily be applied to other cell assays for rare cell retrieval and preservation."
    }, {
      "heading" : "Conflicts of interest",
      "text" : "There are no conflicts to declare."
    }, {
      "heading" : "Acknowledgements",
      "text" : "We thank Ministry of Science and Technology of Taiwan and Genomics Research Center, Academia Sinica, Taiwan for the financial support under contracts MOST-104-2113-M-001-015MY3, MOST 105-0210-01-13-01, MOST 105-2113-M-005-016MY2, MOST 107-2113-M-005-014-, MOST 108-2113-M-005004-, MOST 107-2119-M-001-039-, AS-105-TP-A04, AS-iMATE107-51; Taiwan Ministry of Health and Welfare, under welfare surcharge of tobacco products, No.CMRPG3C1141 for W-S Tsai. We thank Katherine Yih-Ruey Chen for the preparation magnet plate, Dr. Chi-Hua Nieh for the confocal images, Dr. Han-Chung Wu provides antibody EpAb4-1 (anti-EpCAM), and Prof. MawKuen Wu s lab in the Institute of Physics, Academia Sinica, for the SQUID measurements. The confocal microscopy (Leica TCSSP5-AOBS) is one of core facilities in the Institute of Cellular and Organismic Biology, Academia Sinica, Taiwan."
    }, {
      "heading" : "Notes and references",
      "text" : ""
    }, {
      "heading" : "Notes",
      "text" : "Experimental design and performance was reviewed and approved by the Institutional Review Boards of Academia Sinica (oral cancer:AS-IRB01-15009, CRC: AS-IRB01-14031, lung & oral cancer: AS-IRB01-16059, healthy donor: AS-IRB01-14026), Chang Gung Memorial Hospital (CRC: 102-3107B), Taipei Veterans General Hospital (lung cancer: 2016-03-0aaA#1 and oral cancer: 2016-04-011C). Written informed consent was obtained from all patients including healthy volunteer and the cancer patients before the study."
    }, {
      "heading" : "ARTICLE Journal Name",
      "text" : "8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx\nPlease do not adjust margins\nPlease do not adjust margins\nMohamadi and S. O. Kelley, Angew. Chem., Int. Ed.,, 2016, 55, 1252-1265.\n10. C. Alix-Panabieres and K. Pantel, Nat. Rev. Cancer, 2014,\n14, 623-631.\n11. M. Thorsteinsson, G. Söletormos and P. Jess, Anticancer\nRes., 2011, 31, 613-617.\n12. A. Kowalik, M. Kowalewska and S. :_` ` Translational\nResearch, 2017, 185, 58-84.e15.\n13. S. J. Cohen, C. J. A. Punt, N. Iannotti, B. H. Saidman, K. D.\nSabbath, N. Y. Gabrail, J. Picus, M. Morse, E. Mitchell, M. C. Miller, G. V. Doyle, H. Tissing, L. W. M. M. Terstappen and N. J. Meropol, J. Clin. Oncol., 2008, 26, 3213-3221.\n14. J. M. Jackson, M. A. Witek, J. W. Kamande and S. A. Soper,\nChem. Soc. Rev. , 2017, 46, 4245-4280.\n15. M. M. Ferreira, V. C. Ramani and S. S. Jeffrey, Molecular\nOncology, 2016, 10, 374-394.\n16. B. D. Plouffe, S. K. Murthy and L. H. Lewis, Rep. Prog. Phys.,\n2015, 78, 016601-016601.\n17. S. S. Shevkoplyas, A. C. Siegel, R. M. Westervelt, M. G.\nPrentiss and G. M. Whitesides, Lab on a Chip, 2007, 7, 1294-1302.\n18. S. C. Kuo and D. A. Lauffenburger, Biophys. J., 1993, 65,\n2191-2200.\n19. L. L. Kiessling, J. E. Gestwicki and L. E. Strong, Angew.\nChem., Int. Ed., 2006, 45, 2348-2368.\n20. J. E. Gestwicki, C. W. Cairo, L. E. Strong, K. A. Oetjen and L.\nL. Kiessling, J. Am. Chem. Soc., 2002, 124, 14922-14933.\n21. Y.-H. Tang, H.-C. Lin, C.-L. Lai, P.-Y. Chen and C.-H. Lai,\nBiosens. Bioelectron., 2018, 116, 100-107.\n22. C.-H. Lai, J. Hütter, C.-W. Hsu, H. Tanaka, S. Varela-\nAramburu, L. De Cola, B. Lepenies and P. H. Seeberger, Nano Letters, 2016, 16, 807-811.\n23. T. D. Farr, C.-H. Lai, D. Grünstein, G. Orts-Gil, C.-C. Wang, P.\nBoehm-Sturm, P. H. Seeberger and C. Harms, Nano Letters, 2014, 14, 2130-2134.\n24. C.-H. Lai, T.-C. Chang, Y.-J. Chuang, D.-L. Tzou and C.-C. Lin,\nBioconjugate Chem., 2013, 24, 1698-1709.\n25. C.-H. Lai, Y.-C. Lin, F.-I. Chou, C.-F. Liang, E.-W. Lin, Y.-J.\nChuang and C.-C. Lin, Chem. Commun., 2012, 48, 612-614.\n26. C.-H. Lai, C.-Y. Lin, H.-T. Wu, H.-S. Chan, Y.-J. Chuang, C.-T.\nChen and C.-C. Lin, Adv. Funct. Mater., 2010, 20, 3948- 3958.\n27. C.-H. Lai, N.-C. Lai, Y.-J. Chuang, F.-I. Chou, C.-M. Yang and\nC.-C. Lin, Nanoscale, 2013, 5, 9412-9418.\n28. M. Delbianco, P. Bharate, S. Varela-Aramburu and P. H.\nSeeberger, Chem. Rev., 2016, 116, 1693-1752.\n29. Y. Chen, W. Wang, D. Tyagi, A. J. Carrier, S. Cui, S. He and X.\nZhang, Nanoscale, 2019, DOI: 10.1039/C9NR00364A.\n30. Z. Qi, P. Bharate, C.-H. Lai, B. Ziem, C. Böttcher, A. Schulz,\nF. Beckert, B. Hatting, R. Mülhaupt, P. H. Seeberger and R. Haag, Nano Letters, 2015, 15, 6051-6057.\n31. N. Willems, A. Urtizberea, A. F. Verre, M. Iliut, M.\nLelimousin, M. Hirtz, A. Vijayaraghavan and M. S. P. Sansom, ACS Nano, 2017, 11, 1613-1625.\n32. Y. Okamoto, K. Tsuzuki, S. Iwasa, R. Ishikawa, A. Sandhu\nand R. Tero, J. Phys. Conf. Ser., 2012, 352, 012017.\n33. J.-C. Wu, P.-Y. Tseng, W.-S. Tsai, M.-Y. Liao, S.-H. Lu, C. W.\nFrank, J.-S. Chen, H.-C. Wu and Y.-C. Chang, Biomaterials, 2013, 34, 5191-5199.\n34. J.-Y. Chen, W.-S. Tsai, H.-J. Shao, J.-C. Wu, J.-M. Lai, S.-H. Lu,\nT.-F. Hung, C.-T. Yang, L.-C. Wu, J.-S. Chen, W.-H. Lee and Y.-C. Chang, PLoS ONE, 2016, 11, e0149633.\n35. P.-Y. Yeh, Y.-R. Chen, C.-F. Wang and Y.-C. Chang,\nBiomacromolecules, 2018, 19, 426-437.\n36. Z. Liu, S. Chen, B. Liu, J. Wu, Y. Zhou, L. He, J. Ding and J. Liu,\nAnal. Chem., 2014, 86, 12229-12235.\n37. C.-H. Lai, S. Choon Lim, L.-C. Wu, C.-F. Wang, W.-S. Tsai, H.-\nC. Wu and Y.-C. Chang, Chem. Commun., 2017, 53, 4152- 4155.\n38. P. C. Lin, P. H. Chou, S. H. Chen, H. K. Liao, K. Y. Wang, Y. J.\nChen and C. C. Lin, Small, 2006, 2, 485-489.\n39. R. A. Roggers, V. S. Y. Lin and B. G. Trewyn, Mol. Pharm.,\n2012, 9, 2770-2777.\n40. K.-H. Liao, Y.-S. Lin, C. W. Macosko and C. L. Haynes, ACS\nAppl. Mater. Interfaces, 2011, 3, 2607-2615.\nPage 8 of 9Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D\nPage 9 of 9 Nanoscale\nN an\nos ca\nle A\ncc ep\nte d\nM an\nus cr\nip t\nPu bl\nis he\nd on\n3 0\nA ug\nus t 2\n01 9.\nD ow\nnl oa\nde d\nby L\nud w\nig M\nax im\nili an\ns U\nni ve\nrs ita\net M\nue nc\nhe n\non 9\n/2 /2\n01 9\n9: 20\n:2 7\nA M\n.\nView Article Online DOI: 10.1039/C9NR06256D"
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2019,
    "abstractText" : "Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. Accepted Manuscript View Article Online",
    "creator" : "Aspose Ltd."
  }
}